MEDICINE HAT, Caanada - An official for Medicine Hat in southeastern Alberta says the rat population found in the city's landfill appears to be spreading to cushier digs.
View post:
Rats relocating: rodents spread out from landfill in Medicine Hat, Alta.
PHILADELPHIA The Perelman School of Medicine at the University of Pennsylvania has been awarded a $12 million grant from the National Institutes of Health to fund a new Center of Excellence in Prostate Cancer Disparities.
The gap in prostate cancer mortality rates among black and white men -- 62 per 100,000 in African American men and 26 per 100,000 men of European ancestry is wider than that observed in any other major cancer. By combining transdisciplinary, translational research about the effects of biological, behavioral, social, environmental, and health care factors on prostate cancer outcomes, the new centers investigators aim to develop and disseminate interventions that can be used to shrink those striking disparities.
The project will have three prongs. First, the Penn Medicine team will investigate the role of obesity in prostate cancer development and progression of the disease. Though obesity is a potentially modifiable risk factor, its not yet clear how racial composition of a neighborhood, socioeconomic status, living conditions and stress levels relate to obesitys role in disease outcomes. They will also focus on biomarkers and neighborhood data to develop a model to help predict prostate cancer outcomes, and investigate differences in treatment experienced by black and white men as impacted by various barriers to care in an urban environment.
Prostate cancer is a serious public health issue, particularly for African American men says the projects principal investigator, Timothy Rebbeck, PhD, a professor of Epidemiology who directs the Center for Genetics and Complex Traits in the Perelman School of Medicine and serves as associate director for Population Science in the Abramson Cancer Center. Our new center will address the causes of this health disparity. We will be able to use the information from this project to improve the outcomes of African American men who are diagnosed with prostate cancer.
###
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
The rest is here:
Penn Medicine Receives $12 Million to Tackle Prostate Cancer Disparities
AUSTIN, Texas, Aug. 20, 2012 /PRNewswire/ -- The DAOM will be the second regionally accredited Doctorate in Acupuncture and Oriental medicine in the U.S. according to AOMA president, William Morris. "This is a significant achievement for our institution." Since its founding in 1993, AOMA has grown by every important quantitative and qualitative measure including its student body, faculty, accreditation, campus facilities, patients served and community outreach.
The Doctor of Acupuncture and Oriental Medicine (DAOM) is a post-graduate clinical doctorate. AOMA's doctoral program will offer a clinical specialty focus on the management and care of patients with pain and associated psycho-social disorders.
Faculty participation was particularly key to the success of this proposal: Drs. Wu, He, Zeng, Song, Liu, and Mandyam made significant contributions, as well as several staff members. Such participation is essential to accrediting processes for such programs. The Accreditation Commission for Acupuncture and Oriental Medicine (ACAOM) has approved the substantive change proposal for the doctoral program. AOMA's regional accreditor, the Commission on Colleges of the Southern Association of Colleges and Schools (SACS) approved the new program in December 2011.
AOMA's vision of Oriental medical scholarship includes developing advanced clinical specialists, collaborators, educators, researchers, and leaders. "A doctoral program at AOMA builds upon an already strong master's program and provide our graduates and other practitioners with an opportunity for continued study and career development," Morris said.
With an internationally renowned faculty, strong leadership, regional accreditation, demonstrated student success, and now a doctoral degree, AOMA's reputation as a national leader in the field of acupuncture and Chinese medicine education, health care and policy-making continues to grow.
AOMA Graduate School of Integrative Medicine offers a masters-level program in acupuncture and Oriental medicine, preparing its students for careers as skilled, professional practitioners. AOMA is known for its internationally recognized faculty, award-winning student clinical internship program, and herbal medicine program. AOMA conducts more than 20,000 patient visits annually in its student and professional clinics, collaborates with Western healthcare institutions including the Seton Family of Hospitals, and gives back to the community through partnerships with nonprofit organizations and by providing free and reduced price treatments to people who cannot afford them. AOMA is located in Austin, Texas.
For more information, contact: Anne Province, 512-492-3051; 512-497-2925 aprovince@aoma.edu
Visit link:
AOMA to Offer Doctoral Degree in Acupuncture and Oriental Medicine
MORTON GROVE, IL--(Marketwire -08/21/12)- Wolf D. Peddinghaus, M.D., an internal medicine physician, who is on staff at Saint Francis Hospital in Evanston, joined Resurrection Medical Group, a group of over 260 physicians who provide primary and specialty medical care at more than 60 locations throughout Illinois.
Fluent in German, Dr. Peddinghaus earned his medical degree from the University of Heidelberg in Germany, and completed a residency in internal medicine at Saint Francis Hospital in Evanston. He is a board-certified internal medicine physician and has a strong interest in geriatric medicine and elder care.
His clinical interests include health maintenance and prevention, geriatrics and long-term care issues. His philosophy is to treat the whole person -- body and mind. "As an internist, I like coordinating care for my patients so they get the best possible results," said Dr. Peddinghaus.
His office is located at 5747 Dempster St., Ste. 300 in Morton Grove. Office hours are: Monday, Tuesday and Thursday 10 a.m. - 5 p.m., and Friday 1 - 5 p.m. Patients can call 847-324-8700 to schedule an appointment or visit RMG.reshealth.org for more information.
About Resurrection Medical Group A physician-led and patient-focused medical group representing a broad spectrum of primary and specialty care, Resurrection Medical Group provides accessible, quality care and excellent service throughout the greater Chicagoland area. Resurrection Medical Group is part of the new ministry of Provena Health and Resurrection Health Care, now joined as Presence Health. To find a Resurrection Medical Group physician near you, call 855-RES-DOCS (855) 737-3627 or visit us online at rmg.reshealth.org.
About Provena Health - Resurrection Health Care - Now Joined As Presence HealthPresence Health is a family of Catholic, not-for profit, healthcare services providing advanced medical care and exceptional service with compassion and hope. Visit http://www.provenaresurrection.org to learn more.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2071129
Excerpt from:
Resurrection Medical Group Welcomes New Internal Medicine Physician
Rejuv Medical is now providing Anti-Aging Medicine, Stress Reduction and Hormone Balancing.Minnesota (PRWEB) August 20, 2012 Rejuv Medical out of Minnesota is now offering Anti-Aging Medicine, Stress Reduction and Hormone Balancing services. The company, which is under the direction of Joel Baumgartner, M.D., helps people to re-pattern their bodies and supply the elements necessary to balance ...
Read more here:
A medicine originally developed to fight a life-threatening disease may become a type of birth control... for men! It may sound odd but researchers in Boston gave lab mice an experimental medicine called JQ1.
See the original post:
Medicine developed for cancer could be "birth control for men"
The Right Medicine can do wonders for individuals with specific issues. Think about the question, Which Medicine Actually Works? well, thats a good question, and theres a good answer. If you have the right medicine that works specifically for you, it can solve various issues, and the same medicine will work with other people if they have the same problem. There are skilled people who can help evaluate your situation, and give a review on what they think is an issue. Special People with Special Skills can do Special Things.
This entry was posted on Sunday, August 19th, 2012 at 6:21 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Read the original:
A protein-blocking compound has been found to impair sperm production in mice without the use of hormones
By Roxanne Khamsi
The discovery of a hormone-free way to immobilize sperm in mice could lead to the development of oral contraceptives for men. (This image actually shows Eucalyptus macrocarpa stamens under high magnification, which somewhat resemble sperm cells swimming en masse.) Image: flickr/Squil
Showcasing more than fifty of the most provocative, original, and significant online essays from 2011, The Best Science Writing Online 2012 will change the way...
Read More
From Nature Medicine's "Spoonful of Medicine" blog:
The serendipitous finding that a potential cancer-fighting compound temporarily halts sperm production in mice has seeded new hopes for a reversible male contraceptive pill. At a time when the only non-hormonal contraceptive choices for men consist of condoms and vasectomies, the finding, published today in the journal Cell, has stirred the interest of pharmaceutical companies, although its quite far from entering clinical trials.
Several new contraceptives that rely on steroid hormones are in the works to reduce sperm production in men. However, most products developed to date seem to carry undesirable side effects, such as acne and perturbations of cholesterol levels. So, scientists have sought to halt sperm production with compounds that do not alter hormones, targeting everything from calcium ion channels on the tails of sperm to the production of retinoic acid, a metabolite of Vitamin A that has a role in their development. A team led by Dolores Mruk at the Population Councils Center for Biomedical Research in New York has even reported in Nature Medicine on the discovery of a chemical compound known as Adjudin that can stop sperm-forming cells from adhering to the Sertoli cells that nurture them.
The new findings announced today also describe a non-hormonal drug for stopping spermbut contraception was the furthest thing from the minds of James Bradner and his colleagues at the Dana-Farber Cancer Institute who initially developed the experimental compound.
As we reported last year, Bradners team had investigated a small molecule called JQ1 for its ability to thwart cancer by acting on a protein named BRD4. They showed success in mice with multiple myeloma, and other groups soon reported similar findings in animal models of leukemia and lymphoma. Bradner has been downright evangelical about the drug ever since, shipping it to more than 250 labs worldwide, according to a profile of Bradner published last week in Nature.
Link:
Cancer-Fighting Compound Might Double as Reversible Male Contraceptive
One of the sharpest dividing lines between conservatives and liberals is whether or not markets can work in medicine. Progressives admit to being “deeply suspicious of the claim that a health care system dominated by powerful vested interests and mystifying in its complexity can be tamed by consumers who are [...]
Follow this link:
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/vxwrkb/personalized_medic) has announced the addition of the "Personalized Medicine - A Global Market Overview" report to their offering.
This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.
The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.
This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology.
The report covers the brief business profiles of 56 key global players and 77 major players across the United States - 45; Europe - 24; and Rest of World - 8.
The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.
For more information, including table of contents and list of companies mentioned, please visit http://www.researchandmarkets.com/research/vxwrkb/personalized_medic
Read more:
Research and Markets: Personalized Medicine - A Global Market Overview
BOCA RATON, FL--(Marketwire -08/16/12)- Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, announced today the availability of EMA Dermatology with Logical Images' VisualDx, a comprehensive digital medical image library, proving the company's dedication to bringing dermatologists the most powerful EMR on the market.
Modernizing Medicine's user-friendly EMA features algorithms that help to improve medical decision making and information tracking, simplify billing and speed up medical documentation, saving physicians and their staff valuable time. In two years, Modernizing Medicine has captured over 10% of the dermatology market and is currently used by over 550 specialty-specific healthcare practices across the country.
Logical Images' VisualDx is a massively hyperlinked visual thesaurus of over 1,200 dermatology conditions represented by over 25,000 high-resolution medical images. VisualDx captures disease variation by age, body location, skin type, immune status, disease stage, disease severity, lesion type and more, showing how each might look at different stages and in people of different ages and ethnicities. VisualDx is especially helpful in identifying uncommon conditions.
The addition of VisualDx to Modernizing Medicine's powerful EMA Dermatology product will assist dermatologists further at point of diagnosis and promote patient engagement by sharing real medical images patients can relate to. Modernizing Medicine intends to make VisualDx available to all new and existing EMA Dermatology clients.
"I commend Modernizing Medicine for the EMA-VisualDx implementation. Now, in seconds dermatologists can access the best medical images in the world which will help in educating patients right in the exam room," said Art Papier, CEO of Logical Images. "VisualDx on the iPad is a great example of a novel technology that helps to create a bond between physician and patient. Patients have a hard time understanding our spoken medical language, but they easily understand pictures. Images are everything in dermatology, and EMA is now delivering the best medical image collection through VisualDx in seconds. It speeds practice and helps patients. That is what busy physicians want."
"We're confident that the addition of Local Images' VisualDx to EMA Dermatology will help dermatologists make more accurate and complete diagnoses and treatment plans for their patients and will save them and their staff even more time than EMA already does," says Modernizing Medicine co-founder and dermatologist Michael Sherling. "The addition demonstrates our dedication to the dermatology market and the development of the most valuable technology for specialty-specific practices."
EMA Dermatology demos complete with the new VisualDx feature will be available at the Modernizing Medicine booth, #809, during the Summer AAD meeting in Boston this week. Modernizing Medicine will also host a cocktail reception for its customers and press on August 17th, at Top of the Hub, which will feature a presentation by coding, documentation and reimbursement expert, Inga Ellzey. If you'd like to attend, please reach out to Chelsea Boudreaux, at chelsea.boudreaux@atomicpr.com.
About Modernizing MedicineModernizing Medicine is delivering the next generation of electronic medical records (EMR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based specialty-specific EMR with a tremendous amount of medical content already built-in that saves physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with over 400 different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, and optometry markets, and to more than 550 practices across the country.
About Logical ImagesBased in Rochester, NY, Logical Images develops visual health care tools to elevate diagnostic accuracy, enhance medical education, and heighten patient knowledge. Selected by Modern Healthcare Magazine as one of the "Best Places to Work in Healthcare" in 2009, Logical Images is a company of digital imaging experts, leaders in computer-based design and knowledge management, skilled image archivists, and practicing physicians. The company's products include VisualDx, a visual clinical decision support system for diagnostic accuracy, and Skinsight, an online consumer skin health and wellness resource. Logical Images has developed the most comprehensive digital medical image library including 60,000 images representing all ages and skin types. This extensive collection is the foundation for both the VisualDx professional tool and the Skinsight consumer tool -- designed to speed disease recognition for faster, more accurate decision making and patient understanding.
Visit link:
NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
`Personalized Medicine can mean a lot of things to a lot of people. For some, it may relate to doctors having knowledge about their case history and the treatment received, which is a morale boosting factor, since everybody wants caregivers who can comprehend an individual's problems. The day is not very far when this level of personal or individual understanding between a patient and a doctor would be much deeper than hitherto anticipated. The coming decade is expected to witness an increase in the use of companion diagnostics and personalized medicines, with pricing incentives and efficiency improvement propelling the market. Current market leaders with diagnostic divisions focusing on biomarker identification would be at an advantage.
This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.
The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.
This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology. The report covers the brief business profiles of 56 key global players and 77 major players across the United States 45; Europe 24; and Rest of World 8. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.
PART A: GLOBAL MARKET PERSPECTIVE
1. INTRODUCTION1.1 Product Outline1.1.1 Personalized Medicine's Influence on Large Scale Studies1.1.2 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine1.1.3 Ramifications of Personalized Medicine for Healthcare Systems1.1.3.1 Pharmaceutical Industry1.1.3.2 Diagnostics Industry1.1.3.3 Insurers1.1.3.4 Physicians1.1.3.5 Government Agencies1.1.3.6 Patients1.1.4 Analysis of Personalized Medicine by Segment1.1.4.1 Targeted Biologics1.1.4.1.1 Overview1.1.4.1.2 Targeted Biologics for Breast Cancer: An Illustration1.1.4.2 Proteomics & Genomics1.1.4.2.1 Proteomics1.1.4.2.1.1 A Complex Problem1.1.4.2.1.2 Post-Translational Modifications1.1.4.2.1.3 Phosphorylation1.1.4.2.1.4 Ubiquitination1.1.4.2.1.5 Other Modifications1.1.4.2.2 Genomics1.1.4.2.2.1 Pharmacogenomics1.1.4.3 Genetically Modified (GM) Products1.1.4.3.1 The Genetic Engineering Process1.1.4.3.1.1 Applications of Genetic Engineering1.1.4.4 Wellness & Disease Management1.1.4.4.1 Wellness Defined1.1.4.4.2 Disease Management Defined1.1.4.5 Molecular Diagnostic Technologies1.1.4.5.1 DNA Sequencing1.1.4.5.2 Biochips and Microarrays1.1.4.5.3 Cytogenetics1.1.4.5.3.1 Personalized Medicine Based on Molecular Cytogenetics1.1.4.5.3.2 Personalized Medicine Based on Cytomics1.1.4.5.4 Single Nucleotide Polymorphism (SNP) Genotyping1.1.4.5.4.1 Applications of SNPs Pertinent to Personalized Medicine1.1.4.5.5 Haplotyping1.1.4.5.6 Application of Proteomics In Molecular Diagnosis1.1.4.5.7 Gene Expression Profiling1.1.4.5.8 Personalized Medicine and Molecular Imaging1.1.4.5.9 Diagnostics Based On Glycomics1.1.4.5.10 Combining Diagnostics and Therapeutics1.1.4.5.11 Point-Of-Care (POC) Diagnosis1.1.4.5.12 Genetic Testing For Disease Predisposition1.1.5 Analysis of Personalized Medicine by Technology1.1.5.1 Pharmacogenomics1.1.5.1.1 Drug Metabolism1.1.5.1.2 Applications1.1.5.2 Point-of-Care Testing1.1.5.2.1 Tests that are Most Apt for Specific Scenarios1.1.5.2.2 Advantages1.1.5.3 Stem Cell Therapy1.1.5.3.1 Treatment with Stem Cells1.1.5.3.2 Current Therapies1.1.5.3.3 Future Treatments1.1.5.4 Pharmacoproteomics1.1.5.5 Pharmacogenetics1.1.5.5.1 Prediction of Drug-Drug Interactions1.1.5.5.2 Integration of Pharmacogenetics with the Healthcare System1.1.5.5.3 Pharmacogenetic Tests1.1.5.6 Other Personalized Medicine Technologies1.1.5.6.1 Biochips1.1.5.6.2 Genetic Screening1.1.5.6.3 Metabolomics1.1.5.6.4 Molecular Diagnostics1.1.5.6.5 Pharmacodynamics1.1.5.6.6 Pharmacokinetics1.1.5.6.7 SNP Genotyping1.1.6 The Rationale Behind Personalized Medicine: "One Size no Longer Fits All"1.1.7 The Human Genome: What is It?
2. KEY MARKET TRENDS
Combating Melanoma and Lung Cancer Facilitated Using Novel Personalized Drugs
Go here to see the original:
SAN FRANCISCO, CA and TOKYO--(Marketwire -08/15/12)- Medivation, Inc. (MDVN) and Astellas Pharma Inc. (Tokyo:4503) today announced the publication in the New England Journal of Medicine of the results from the Phase 3 AFFIRM trial, an international, randomized, double-blind, placebo-controlled clinical study of enzalutamide (formerly MDV3100) in men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy. The paper, "Increased Survival with Enzalutamide in Prostate Cancer After Chemotherapy," appears in the August 15 online issue of the Journal.(1)
"The AFFIRM data represent an important body of clinical evidence on enzalutamide, a novel oral androgen receptor signaling inhibitor, as a potential new treatment that can prolong the lives of men with advanced prostate cancer. The achievement underlines the importance of integrating clinical observations and basic research to significantly improve patient outcomes and bring therapies to patients faster. It is extremely gratifying to share these results with the medical community," said Howard I. Scher, M.D., chief, Genitourinary Oncology Service at Memorial-Sloan Kettering Cancer Center, the co-principal investigator and lead author of the AFFIRM study paper.
In the AFFIRM trial, the data showed that enzalutamide exhibited a statistically significant benefit in overall survival compared to placebo. Men treated with enzalutamide had a median overall survival of 18.4 months (95% confidence interval, 17.3 to not yet reached) compared to 13.6 months (95% confidence interval 11.3 -15.8) for men treated with placebo (hazard ratio 0.63; p < 0.0001), representing a 37 percent reduction in the risk of death.
In the Phase 3 AFFIRM trial three most common side effects observed more frequently in enzalutamide as compared with placebo-treated patients included fatigue, diarrhea and hot flush. Seizure was reported in less than 1% of enzalutamide-treated patients. Serious adverse events were lower in the enzalutamide group than in the placebo group.
About Enzalutamide (formerly MDV3100)Enzalutamide is an oral, once-daily investigational agent that is an androgen receptor signaling inhibitor. Enzalutamide inhibits androgen receptor signaling in three distinct ways: it inhibits 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors. Medivation and Astellas announced on July 24, 2012 that the U.S. Food and Drug Administration accepted the enzalutamide New Drug Application filing for review and granted Priority Review Designation.
About Medivation Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com.
About Astellas Pharma Inc.Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global category leader in Oncology, and has several oncology compounds in development in addition to enzalutamide. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com/en.
(1)Scher, HI, et al. Increased Survival with Enzalutamide in Prostate Cancer After Chemotherapy. New Engl J Med. 2012; 367.
See more here:
New England Journal of Medicine Publishes Results From Phase 3 AFFIRM Trial of Enzalutamide
RealTime Medicine is new service that allows patients to consult with a doctor live and face-to-face through video, phone or email from anywhere!Houston, TX (PRWEB) August 15, 2012 RealTime Medicine is new service that allows patients to consult with a doctor live and face-to-face through video, phone or email from anywhere! This revolutionary way of healthcare delivery provides patients with on ...
Read more:
Mary Ann Benitez and Johnny Lo
Thursday, August 16, 2012
The development of Chinese medicine in the hope of making Hong Kong a herbal hub will not affect the progress of Western medicine, Secretary for Food and Health Ko Wing-man insists.
This comes after the announcement that the public Kwong Wah Hospital in Yau Ma Tei will have at least 50 beds for integrated Chinese and Western medicine in-patient treatment when a two-phase HK$8 billion redevelopment project is completed by 2022.
But the three Hong Kong universities that have schools of Chinese medicine are seeking funds to join in a project to set up a Chinese medicine hospital before then, Ko noted yesterday.
That will not affect development of Western medicine, he said at an Eu Yan Sang Charitable Foundation function.
"On the contrary, the development of Chinese medicine hopefully may help in alleviating some pressure on our public hospital system on the Western medical side, in particular primary care and rehabilitation services."
Ko also told RTHK yesterday that he expects Chinese medicine to help people recovering from strokes, cancer and arthritis after receiving Western treatment and surgery.
He added that "organizations including local universities' schools of Chinese medicine, are raising funds to build a hospital focusing on Chinese medicine."
It is the right time to take Chinese medicine forward, Ko added. There is a legal framework for registration of practitioners and herbal products, and research at public hospitals continues.
Read more from the original source:
NEW YORK, Aug. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
In February 2010, Frost & Sullivan surveyed 157 vascular surgeons, interventional cardiologists, and interventional radiologists on a broad range of issues relating to peripheral intervention procedures. This study is based on their responses to an extensive online questionnaire. The study addresses balloons and stents, atherectomy devices, thrombectomy devices, and endovenous ablation. A wide variety of topics are covered in the study, including respondents' purchasing authority; referral pathways; treatment selection criteria; patient awareness of/receptivity to treatment options; procedures currently in use and likely to be adopted; and primary, secondary, and last-resort treatment options by pathology.
Balloons and stents Atherectomy devices
Topics covered in the study include:
Respondents' purchasing authority
Referral pathways
Treatment selection criteria
Patient awareness of/receptivity to treatment options
Procedures currently used and likely to be adopted
Excerpt from:
Related To Story
POSTED: 7:01 pm PDT August 14, 2012
UPDATED: 7:03 pm PDT August 14, 2012
Copyright 2012 by City News Service. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Visit link:
A small molecule agent like methylene blue that has been grandfathered into approved use as a diagnostic tool in humans can be studied further as possible treatment for the neurodegenerative illness
By Kathleen Raven
Methylene blue Image: Flickr/amandabhslater
Showcasing more than fifty of the most provocative, original, and significant online essays from 2011, The Best Science Writing Online 2012 will change the way...
Read More
FromNature Medicine's"Spoonful of Medicine" blog:
A compound already sitting on the shelves of biomedical laboratories and emergency room supply closets seems to interrupt the formation of neurodegenerative protein clumps found in Huntingtons disease, according to a preliminary animalstudypublished August 7 in theJournal of Neuroscience.
This versatile agent, called methylene blue, gets a mention in medical literature asearlyas 1897 and was used to treat, at one time or another, ailments ranging frommalariato cyanidepoisoning. The U.S. Food and Drug Administration has never formally approved it as a therapy for any illnesses. But that fact hasnt stopped biomedical researchers from tinkering with the agents apparent ability toimprovecognitive function. And although the new paper out today relies on a Huntingtons disease model in flies and mice, scientists are hopeful. "Because of existing knowledge of methylene blue and the fact that its not harmful to humans, I would hope that progress toward clinical trials could go relatively quickly," saysLeslie Thompson, a neurobiologist at University of CaliforniaIrvine and lead author on the new study.
Huntingtonsdiseaseoccurs when the C-A-G sequence of DNA base pairs repeat too often on theHTTgene, resulting in an abnormally long version of the huntingtin protein, that therefore folds incorrectly and forms clumps in the brain. The illness usually begins to affect people in their 30s and 40s, causing movement problems and early death. No drug is currently available to stop the disease from progressing.
For their experiment, researchers fed methylene blue mixed with food for a week toDrosophilaflies engineered to carry a mutated copy of theHTTgene. An examination of the flies brains showed that protein clumps had been reduced by 87 percent compared with a control group. Meanwhile, mice designed to carry the mutated gene were given methylene blue and underwent several tests to assess mobility. At two months of age, the treated mice showed abnormal clasping of their hind claws only 20 percent of the time in a reflex test, whereas their untreated counterparts clasped at a 60 percent rate. (Less clasping meant healthier mice.) While the number of mice used was not sufficient to provide statistically significant results and the difference in the test quickly dropped off at nine weeks of age, Thompson still views the data as hopeful, because even a delay in Huntingtons symptoms would be very helpful. Thompson quickly points out that more research is needed. "The early steps of aggregation [protein clumping] are getting altered in a test tube, in flies and in miceand thats significant," she says, and speculates that methylene blue may possibly prevent the mutantHttprotein from sticking to itself.
See the article here:
Common Lab Dye Found to Interrupt Formation of Huntington's Disease Proteins
Public release date: 13-Aug-2012 [ | E-mail | Share ]
Contact: Samuel Smith newsbureau@mayo.edu 507-284-5005 Mayo Clinic
ROCHESTER, Minn. -- Mayo Clinic's Individualizing Medicine Conference, scheduled for Oct. 1-3, will draw experts from around the world to discuss the use of genomics in patient care. Physicians and researchers in this rapidly growing field are building a new type of medicine based on the genomic and molecular interactions that make each patient unique. At Mayo Clinic, the Center for Individualized Medicine is making these discoveries and building a clinical practice that delivers genomic medicine as part of routine care.
Conference sessions will be accessible to journalists through the News Network. Media may register for the site http://newsnetwork.mayoclinic.org/register/.
This inaugural conference, Individualizing Medicine 2012, will be held at the Mayo Civic Center in Rochester. Presentations will range from cutting-edge diagnostics and experimental cancer treatments to the most ethical and respectful ways to manage patient genomic information. An introduction to individualized medicine will be presented for those unfamiliar with the field.
"The technologies of genome sequencing have made tremendous strides over the past few years. The time needed to sequence and interpret whole genomes is no longer the seemingly insurmountable barrier it once was due to the use of these tools in the everyday care of our patients," says Gianrico Farrugia, M.D., director of Mayo Clinic's Center for Individualized Medicine, which is holding the event.
"Right now, we are building genomics technologies into our laboratories and electronic medical records," Dr. Farrugia says. "This conference will be a place for both doctors and scientists to develop real-world strategies for incorporating genomics into the clinical practice."
Conference highlights include:
###
About Mayo Clinic
Read more:
NEW YORK, Aug. 14, 2012 /PRNewswire/ --EHE International, the nation's largest specialty preventive medicine practice organization, announced today that it has immediate market opportunities for qualified physician practice groups to join its private network to accommodate this growth. Entering its centennial year, EHE International is the recognized leader in employer-sponsored preventive medicine programs. These programs are designed for the early detection of life-threatening chronic disease and its associated life-style behaviors by way of comprehensive physical exams and clinical counseling.
"2012 has been a year of exceptional growth for EHE International," said Deborah McKeever, the company's president. "This growth stems from Fortune 500 employers including EHE International's physician-led preventive care programs under their self-insured medical plans. Our clinical protocols are specifically designed for the early detection of disease and to identify health risks and lifestyle behaviors attributable to preventable chronic disease." EHE International's patient care protocols are developed by an independent Medical Advisory Board with expertise in evidence-based preventive medicine.
The company's private network of certified physician partners offering EHE International's programs spans 42 states. "Each employee receives a comprehensive annual physical exam complemented by preventive medicine screenings that are aligned with their age, gender, family and personal health histories, and personal need. These include extensive blood and urine analysis, mammograms, cardiac stress testing, vascular screening, and colonoscopies, all as deemed medically appropriate," said McKeever.
Immediate new and expanded market opportunities for internal medicine, radiology, cardiology, and gastroenterology specialists are now open in Alabama, Alaska, Arkansas, California, Connecticut, Florida, Georgia, Kentucky, Missouri, New York, North Carolina, Ohio, South Carolina, Texas, Vermont, Virginia, and Wisconsin. Interested physicians and physician practice managers should contact EHE International Director Michael Pokrywka at 212.332.3025 or mpokrywka@eheintl.com.
"The rate of growth and demand for our services we're experiencing is unrelated to the recent passing of the Affordable Care Act, but rather comes from employers who recognize that their [often] long-standing inclusion of covered preventive benefits in their medical plans has not, cannot yield effective measures in cost reduction of preventable disease in of themselves," says McKeever. "Since we first opened our doors in 1913, preventing disease been EHE International's philosophy. Seems like we were onto something thenand now."
About EHE International
Since 1913, EHE International has been the nationally recognized leader in preventive medicine programs. Its clinical protocols are specifically designed for early detection of preventable disease and associated risk factors, supported by robust personal coaching and health management tools and resources. EHE International is the oldest and largest preventive medicine specialist and its clinically based educational and social engagement platforms are the preferred choice among America's leading employers. For more information, visit http://www.eheintl.com.
View post:
EHE International Announces Nationwide Expansion of Its Physician Network